CDD Vault Overview: Features, Pricing & Who It’s For (2026)
CDD Vault is the pragmatist’s drug discovery platform — a hosted, modular informatics system covering chemical registration, bioassay data management, SAR analysis, ELN and inventory, built around being genuinely usable by both chemists and biologists from day one. Its defining advantages are speed and cost: reviewers report deployments live within days to a week, and “the price” appears repeatedly as the stated reason for choosing it. The trade-offs are equally clear — graphing capability that sends users back to GraphPad Prism, and sample-lifecycle depth that stops at compound inventory rather than full LIMS coverage. Best for: small-to-mid-sized discovery teams, biotech startups, academic drug discovery labs, and distributed collaborations that need chemistry–biology data unified without an enterprise implementation project. Consider alternatives if: you need enterprise-scale governance across many sites, full LIMS sample lifecycle management, or publication-grade graphing inside the platform. What CDD Vault is CDD Vault is the flagship product of Collaborative Drug Discovery, founded in 2004 and based in Burlingame, California — making it one of the longer-established independents in discovery informatics, and notably still independent in a market that has consolidated heavily. The platform is a comprehensive SaaS database and informatics system for drug discovery data, hosted through a web interface, letting multidisciplinary project teams securely manage, analyze and collaborate on chemical and biological data. It serves scientists at academic institutions and biotech or pharmaceutical companies, including collaborative projects spanning both — and extends beyond pure drug discovery into agritechnology, formulation and other research-intensive environments. Its positioning is deliberately different from the enterprise platforms: rather than a governed system of record requiring workflow modelling and a deployment project, CDD Vault aims to be adopted quickly and cheaply by teams that need industrial-grade data management without industrial-grade overhead. Modules and capabilities CDD Vault is sold modularly, which matters for both cost and fit. The core components: Activity & Registration — the chemical registration and assay data backbone, described as a modern web application for chemical registration, assay data management and SAR analysis. The registration system handles both small molecule and biologics data from lab experiments. Electronic Lab Notebook — integrated directly with the chemical and biological assay data repositories and the analysis environment, allowing teams to archive and search experiments and collaborate securely. Users can document research using text, images, tables and files, and design custom ELN forms. Visualization — a dynamic analysis tool for plotting and analyzing large datasets to find patterns, activity hotspots and outliers. Teams can search experiments and results in a SAR table, filter substructures to detect patterns, and measure result quality through heatmap visualizations or plate statistics. Inventory — compound and reagent tracking, letting supervisors maintain compound details, pre-order compounds, allocate resources and track location using barcodes, with visibility across in-house and externally shared stock. APIs and hosting — a fully documented API and secure online hosting, with data flowing between ELN, database, built-in analytics and integrated third-party tools. Additional capabilities reported include curve analytics, workflow automation, AI features, access controls and permissions, audit management, electronic signature and secure data storage. For what regulated environments require of these, see our 21 CFR Part 11 explainer. Strengths Speed to value — the standout differentiator This is where CDD Vault separates itself most sharply from enterprise alternatives. Independent evaluation rates CDD Vault 4.7 out of 5 on implementation services and domain expertise, with users reporting fast time-to-value and deployments often live within days to a week. The vendor’s own framing — that no implementation is needed — is broadly corroborated by an academic user who described the system as easy, flexible and intuitive, requiring nearly zero maintenance. Set that against the enterprise discovery platforms, where reviewers consistently report lengthy setup and heavy coordination, and the contrast defines who each product serves. Our implementation timeline guide covers why this gap matters so much in practice. Cost-effectiveness Affordability is the most consistently cited reason users choose CDD Vault. One reviewer’s stated reason for choosing the platform was simply “The price!” Another, who had experience with Daylight, Modgraph, CambridgeSoft, Dotmatics and ChemAxon, returned to CDD when joining a new startup, citing a very cost-effective, easily customizable and quick way to store, review and retrieve data. An academic user described it as a cost-effective way to recapitulate industrial-style databases in a smaller environment. Genuine chemistry–biology usability The platform’s central claim — that chemists and biologists can both work in it daily — holds up in user accounts. A biologist who brought CDD Vault into a new discovery programme described it as enabling easy data-sharing between chemistry and biology so cross-discipline discussions become clear and productive, with screening data from raw or normalized plate formats linked to compound structures and computed properties making sorting and ranking straightforward. Another reviewer confirmed it serves both biologists and medicinal chemists, and that integration with external resources such as PDB and chemogenomics databases assists in first-step hit characterization. Support quality Support emerges as an unusually strong theme. One reviewer wrote that the support team deserves 13 out of 10 stars, calling it among the best they had received; another described technical support as astonishingly fast and helpful. Independent evaluation notes that the support team includes scientists who understand the domain — a meaningful distinction from generic software support. External collaboration The platform is built for distributed research teams collaborating securely in real time, with flexible controls for sharing data with internal teams and external partners. For academic groups and virtual biotechs coordinating with CROs and collaborators worldwide, this is a core capability rather than a feature. Limitations Graphing is the most consistent complaint. Several reviewers cite limitations in graph customization versus tools like GraphPad Prism. One user was explicit: they like the customizability and the optional ELN, but find the graphs non-adjustable, so figures for papers and grants still go through Prism. This is a workflow friction rather than a functional gap, but plan for a separate graphing tool in your stack. Sample lifecycle depth stops at compound inventory. Some users want broader LIMS-style sample
Dotmatics Overview: Features, Pricing & Who It’s For (2026)
Dotmatics is one of the most complete integrated discovery informatics platform on the market — an ELN, compound and biologics registration, assay data management, and analytics layer, wrapped around a portfolio of applications most scientists already use daily, including GraphPad Prism, SnapGene and Geneious. Its genuine strength is unifying chemistry and biology on one backbone. Its genuine cost is deployment weight: reviewers consistently report lengthy setup and heavy coordination. And the defining fact of 2026 is that Dotmatics is no longer a private-equity-backed independent — Siemens acquired it for $5.1 billion, a change that brings scale and raises questions every prospective buyer should ask. Best for: large discovery organizations, biopharma, CRO/CDMOs and industrial R&D running both chemistry and biology programmes that need a single governed system of record. Consider alternatives if: you’re a small lab wanting a notebook-first tool, you need fast time-to-value, or your workflows are instrument-centric rather than discovery-centric. What Dotmatics is Dotmatics is a scientific R&D platform combining an electronic lab notebook, sample and sequence registration, inventory management, workflow automation, and scientific data search and analytics in one connected system. It targets biopharma, CRO/CDMOs and industrial R&D, positioning itself as a replacement for disconnected point tools and spreadsheets with a governed system of record. What distinguishes it from most ELN vendors is that Dotmatics is not really one product. It is an enterprise platform plus a portfolio of well-known scientific applications assembled through acquisition — a structure that has both compounding advantages and integration challenges. The portfolio: what’s actually included Understanding Dotmatics means understanding its constituent parts, because buyers frequently already own several of them. The platform layer. The ELN & Data Discovery Platform is the core notebook and registration environment, with centralized registration and inventory. Luma, released in October 2023, is the newer AI-native multimodal scientific intelligence platform — a low-code SaaS layer that aggregates data across instruments and software into clean data structures for AI and ML analysis, bringing together instrument outputs, application data and enterprise sources for analysis across biology, chemistry and materials. Cheminformatics. Vortex handles chemical data visualization and analysis, supporting the structure-centric workflows that small-molecule discovery depends on. The applications. This is where Dotmatics’ reach becomes unusual: The strategic logic is integration: connecting Prism outputs, Geneious sequence work and flow cytometry data into the Luma platform so results flow into a single governed environment rather than living in silos. In practice, that integration has been delivered progressively rather than all at once, and how complete it is for your specific combination of tools is a fair demo question. Core capabilities for discovery Compound and biologics registration. Dotmatics spans ELN, BioRegister, compound registration and assay data management — the registration backbone that turns informal chemistry into an institutional asset. Our drug discovery ELN guide explains why this matters more than most feature comparisons suggest. Chemistry–biology unification. Independent review synthesis credits Dotmatics specifically with unifying chemistry, biology and assay data on one backbone — the capability that separates genuine discovery platforms from biology-first notebooks. Compliance and governance. Role-based permissions, audit trails and compliance-ready controls support regulated workflows, with flexible integrations to existing lab and enterprise systems. Dotmatics has also pursued FedRAMP certification for its ELN, relevant for government laboratories and a signal of enterprise security posture. For what regulated environments require, see our 21 CFR Part 11 explainer and LIMS validation guide. Traceability. Scientists can plan and capture experiments, track materials with full chain of custody, and connect results to the right samples, sequences and studies so prior work is findable and reusable. The Siemens acquisition: what buyers should know This is the most consequential development in Dotmatics’ history and deserves direct treatment rather than a footnote. What happened. Siemens announced on 2 April 2025 that it would acquire Dotmatics for $5.1 billion from Insight Partners, and announced completion on 1 July 2025. Dotmatics joined Siemens’ Digital Industries Software business, extending the Siemens Xcelerator portfolio into life sciences. The scale behind the price. Dotmatics was expected to generate more than $300 million in revenue in fiscal 2025, described as highly profitable and cash generative with an adjusted EBITDA margin above 40% and mid-teens revenue growth. Siemens projected revenue synergies of around $100 million per year in the medium term, accelerating to over $500 million long-term, and valued the expanded addressable market at $11 billion. The strategic thesis. Siemens’ stated aim is a first-of-its-kind end-to-end digital thread connecting research data through to production — combining Dotmatics’ scientific platform with Siemens’ digital twin and manufacturing capabilities. For organizations that take molecules from discovery into manufacturing, that vision is genuinely differentiated. The history behind it. Dotmatics reached this point through sustained consolidation. Insight Partners first invested in 2017; Insightful Science acquired Dotmatics in March 2021 in a deal valued at up to $690 million; the combined entity rebranded as Dotmatics in April 2022; and Insight Partners supported 14 strategic acquisitions across that period. By 2022 the company reported more than two million scientists and 10,000 customers. The honest questions for a buyer. Ownership changes of this magnitude affect roadmaps, pricing and support models, and it is legitimate to ask about them directly. Reasonable questions for a sales conversation: how has product roadmap prioritization changed under Siemens; what happens to standalone application licensing (Prism, SnapGene, Geneious) versus platform bundling; whether pricing models are being revised; and how the Siemens integration affects support structures. None of these have publicly known answers, and a vendor who engages with them candidly tells you something useful. Our migration guide covers what vendor changes mean for existing customers. Strengths Genuine chemistry–biology integration, which few competitors match at this depth — the core reason Dotmatics appears on discovery shortlists. Application portfolio reach. Owning Prism, SnapGene and Geneious means Dotmatics is already inside most discovery organizations before any platform conversation begins, and the integration path is shorter than adopting an unfamiliar ecosystem. Strong configurability once workflows are modelled, according to independent review synthesis, with approachable day-to-day usability relative to legacy enterprise LIMS suites —
Waters NuGenesis LMS / SDMS Overview: Features, Pricing & Who It’s For (2026)
Read this first — NuGenesis is not a traditional LIMS Waters itself markets NuGenesis as “LIMS capabilities without the complexity” and as “a unique and powerful alternative to a traditional LIMS” (Waters video; European Pharmaceutical Review launch). If you are evaluating NuGenesis as your laboratory’s primary LIMS — the system that manages all your samples, tests, methods, and compliance workflows — you are likely evaluating the wrong product. NuGenesis is primarily an SDMS (Scientific Data Management System) and ELN platform that sits alongside a traditional LIMS, not in place of one. Its SDK explicitly integrates with external LIMS products (LabWare, Chemware). Its most powerful use case is as the compliance-ready data archive and ELN for labs already running Waters Empower chromatography data system. If your lab uses Empower heavily, NuGenesis is the natural next layer. If your lab does not use Empower and needs a primary LIMS, other vendors in this series serve that need more directly. Waters NuGenesis is a laboratory information management platform that combines a Scientific Data Management System (SDMS), an Electronic Lab Notebook (ELN), and a Sample Management layer into what Waters calls a Lab Management System (LMS). The platform is developed and supported by Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software headquartered in Milford, Massachusetts. Waters was founded in 1958 by James Logan Waters and is known for Empower chromatography data system, MassLynx mass spectrometry software, ACQUITY UPLC and HPLC systems, and the NuGenesis LMS. FY2024 revenue: $2,958 million. Approximately 7,600 employees operating in 35 countries (Waters FY2024 press release). NuGenesis SDMS has been adopted by “hundrends of companies around the world” (waters.com/nugenesis-sdms). The Sumble technology adoption platform identifies 153 organisations currently using NuGenesis (Sumble, April 2026). The platform is available in Japan via Waters Informatics Strategic Partner B-EN-G (Business Engineering Corporation), which publishes implementation templates and a dedicated September 2025 article on NuGenesis for the Japanese biopharma market — confirming active commercial presence in Asia. Named customers include BIOVECTRA, a biotech CDMO serving the pharma industry, which is featured in a waters.com webinar series on ongoing NuGenesis LMS implementation success. This article draws on waters.com (all NuGenesis product pages), the NuGenesis 9.3 What’s New white paper (Waters, January 2024), the Waters 21 CFR Part 11 white paper for NuGenesis SDMS, the Waters Application Programming Interfaces page, the Waters Knowledge Base (AWS deployment article), European Pharmaceutical Review (NuGenesis LMS launch announcement), SelectScience (NuGenesis SDMS product listing and case study), Sumble (technology adoption data), B-EN-G (Waters Informatics Strategic Partner, Japan), Wikipedia (Waters Corporation), Waters FY2024 financial results press release, IntuitionLabs LIMS vs SDMS guide, and a Scispot competitor-authored pricing analysis (November 2025, attributed). Waters Corporation has not reviewed, sponsored, or paid for this article. Understanding Waters — and why NuGenesis exists Waters Corporation has been a dominant force in analytical chemistry instrumentation for over 65 years, particularly in HPLC and UPLC separations and mass spectrometry. Its Empower Chromatography Data System is one of the most widely deployed CDS platforms in pharmaceutical QC globally, with deep regulatory acceptance. The challenge Empower creates is also what NuGenesis solves: Empower generates massive volumes of instrument data — chromatograms, spectra, processing methods, raw files, printouts — that must be securely archived, searchable, auditable, and accessible for years under 21 CFR Part 11 and EU Annex 11 requirements. NuGenesis SDMS was built specifically to address this problem: automatically capture, index, and archive all data flowing out of Empower (and other instruments) into a compliant, searchable central repository without manual intervention. The NuGenesis LMS layer then adds ELN-style documentation, sample submission, results review, and stability testing workflow on top of that repository. This origin is why NuGenesis is most accurately evaluated as “the informatics complement to Empower” rather than as a standalone LIMS. A lab running Empower as its CDS, with no SDMS, has uncontrolled data files sitting on instrument PCs, difficult to back up, audit, or search. NuGenesis SDMS solves that immediately. A lab with no Empower deployment evaluating a primary LIMS would typically look at STARLIMS, LabWare, or Thermo Fisher SampleManager rather than NuGenesis. The Empower + NuGenesis stack The most common NuGenesis deployment pattern, confirmed by the IntuitionLabs LIMS/SDMS guide and the Astrix global biopharma case study, is: Thermo Fisher SampleManager (or another LIMS) manages samples and test results. Waters Empower 3 controls HPLC and UPLC instruments and processes chromatographic data. Waters NuGenesis SDMS automatically archives all Empower data files, raw chromatograms, and printouts into a searchable, 21 CFR Part 11-compliant central repository. In this stack, NuGenesis is not replacing the LIMS — it is adding the SDMS layer that the LIMS cannot provide on its own. At a glance Field Details Product Waters NuGenesis Software — comprising NuGenesis SDMS, NuGenesis LMS (ELN + Sample Management), NuGenesis Sample Management, NuGenesis Stability, and NuGenesis Dashboards. Current version 9.3 (NuGenesis 9.3 What’s New white paper, Waters, January 2024). Supports Empower 3.8 and Windows Server 2016 / 2019. Parent company Waters Corporation (NYSE: WAT). Founded 1958, Milford, Massachusetts, USA. FY2024 revenue: $2,958M. ~7,600 employees. 35 countries. Primary competitors: Agilent Technologies, Thermo Fisher Scientific, Revvity, Danaher (Wikipedia). What it actually is A Scientific Data Management System (SDMS) + ELN + Sample Management platform. NOT a traditional LIMS. Waters markets it explicitly as “LIMS capabilities without the complexity.” External LIMS (LabWare, Chemware) can connect via the NuGenesis SDK. Best understood as the data management and ELN complement to Waters Empower CDS. Primary market Pharmaceutical and biopharma analytical labs, QC labs, R&D, and CDMOs that use Waters Empower as their chromatography data system and need compliant data archiving, scientific search, ELN workflow, sample management, and stability management without deploying a full enterprise LIMS. Adoption “Hundreds of companies around the world” (waters.com SDMS page). 153 organisations confirmed on Sumble (April 2026). Named customer: BIOVECTRA (biotech CDMO, pharma). Waters Informatics Strategic Partner active in Japan: B-EN-G (September 2025 publication). Deployment On-premise (Windows Server). Cloud on AWS is NOT officially supported as of NuGenesis 9.4 per Waters Knowledge Base (WKB305387). The NuGenesis
Revvity Signals Notebook ELN Review: Features, Pricing & Who It’s For (2026)
The defining differentiator for chemists Signals Notebook is the only cloud-native ELN with native, embedded ChemDraw. ChemDraw has been the industry-standard chemical drawing tool since 1985. If your lab includes synthetic chemists who draw structures, calculate stoichiometry, or search by chemical substructure and similarity, Signals Notebook’s native ChemDraw integration is the single most important capability no other ELN in this series can match on equal terms. For labs where biology is the primary discipline and chemical structure handling is not central, this advantage is reduced, and other ELNs may provide equivalent or better value. Signals Notebook is the flagship ELN of Revvity Signals Software, the informatics division of Revvity, Inc. (NYSE: RVTY). It is the most widely adopted ELN in this review series by any measurable scale: 1 million scientists at 4,000 organisations use it (AWS Marketplace). Named customers include Eli Lilly, Roche Diagnostics, AstraZeneca, Merck KGaA, Lundbeck, Givaudan, and FrieslandCampina. Stanford University and the NIH intramural research programme both run it. Revvity Signals Software employs approximately 720 people and serves those 1 million users worldwide (revvitysignals.com/company/about-us). Understanding Signals Notebook requires understanding where it comes from. Revvity’s informatics lineage begins with CambridgeSoft, the company that developed ChemDraw in 1985. CambridgeSoft was sold to PerkinElmer in 2011 (Wikipedia), and its lab notebook product — then called E-Notebook — was developed as an enterprise ELN for decades. In 2022, PerkinElmer split into two independent public companies: the life sciences and diagnostics businesses became Revvity, Inc. (NYSE: RVTY); the applied and enterprise businesses kept the PerkinElmer name and went private. Revvity’s software division became Revvity Signals Software, and Signals Notebook is the cloud-native successor to E-Notebook — rebuilt from scratch on a microservice architecture rather than ported to the cloud (white paper, revvitysignals.com). This article draws on revvitysignals.com (product pages, About Us, case studies, white papers, NEXUS Europe 2025 recap, FAQ pages), the Signals Notebook August 2024 data sheet, the ‘5 Benefits of Signals Notebook’ white paper (January 2025), the Eli Lilly case study (May 2025), AWS Marketplace (product listing and verified reviews), NIH Office of Intramural Research ELN policy (confirmed as active Signals Notebook deployment), Stanford University Science Library (confirmed active licence), G2 (Revvity Signals seller page: 4.4/5, 42 reviews), PeerSpot, ChemDraw Wikipedia article, Wikipedia (Revvity). Revvity Signals has not reviewed, sponsored, or paid for this article. Company and heritage — why the ChemDraw lineage matters Revvity is not a startup building a new ELN. It is the scientific informatics arm of a company with 65+ years of history in life sciences and analytical chemistry, with direct lineage to the most trusted chemical drawing tool in existence. This heritage is operationally relevant: Signals Notebook’s native ChemDraw integration is not a partnership or an API connection — ChemDraw is developed by the same organisation, on the same platform, and updated in lockstep with Signals Notebook. The informatics product line progression is: CambridgeSoft E-Notebook (1990s–2011) → PerkinElmer E-Notebook (2011–2022) → Revvity Signals Notebook (2022–present). Signals Notebook was built cloud-native from the ground up — not a cloud-hosted version of legacy on-premise software. The original E-Notebook product has been sunset. Signals Notebook Standard is the current active product; the Individual Edition reached End of Life on March 1, 2025 (Revvity Signals support portal), with data migration paths to Standard provided. Revvity Signals Software also maintains an exclusive partnership with Spotfire (the TIBCO/Cloud Software Group data analytics platform), embedding it within the Signals platform for scientific data visualisation. This Spotfire relationship provides advanced analytics capability directly connected to ELN data — a combination that is otherwise unavailable in a single vendor stack from any other ELN in this series. On the Revvity corporate context Revvity (NYSE: RVTY) is a publicly traded company with initial revenues of approximately $3 billion (Wikipedia) and approximately 11,000 employees. Revvity Signals Software is one division within Revvity. Lab managers signing multi-year ELN contracts benefit from the vendor stability that public company status provides — financial disclosures, public accountability, and institutional investment discipline. The risk of unexpected acquisition or discontinuation is lower than for small private ELN vendors. The offsetting consideration is that Revvity is a large organisation: product decisions reflect enterprise-wide priorities, not just the ELN user community. At a glance Field Details Product Signals Notebook — cloud-native ELN and scientific collaboration platform Parent company Revvity Signals Software, division of Revvity, Inc. (NYSE: RVTY). HQ: Waltham, Massachusetts, USA. ~11,000 employees (Revvity). ~720 employees (Revvity Signals Software). Origins: CambridgeSoft → PerkinElmer Informatics → Revvity Signals. Scale 1 million scientists at 4,000 organisations worldwide (AWS Marketplace product listing, April 2026). Product type ELN (Electronic Lab Notebook) and scientific collaboration platform. Primary purpose: experiment documentation, data capture, collaboration, IP protection, and regulatory compliance in R&D environments. Architecture Cloud-native SaaS built on AWS. Microservice architecture — each component operates independently; self-healing and resilient. No on-premise version available. Release cadence 10 releases per year (confirmed on product page and FAQ). Updates deployed automatically — no customer IT action required. Free trial Yes — available on revvitysignals.com. No credit card required for trial. ChemDraw Native, embedded integration. The only cloud ELN with ChemDraw. Automates stoichiometry calculations, supports SMILES, CAS Number search, structure/substructure/similarity search. Full access to PubChem safety data sheets. Spotfire Exclusive partnership for scientific data analytics and visualisation. Embedded within the Signals platform for advanced data analysis connected directly to ELN data. Signals DLX Digital Lab Exchange (powered by Scitara): automated instrument data capture, parsing, and organisation directly into Signals Notebook. Eliminates manual transcription from analytical instruments. Signals One Higher-tier offering adding AI-enhanced workflows, structured data handling, structure-activity relationship (SAR) analysis, and deeper data intelligence on top of Signals Notebook foundations. Signals Inventa Enterprise data analytics and management layer for the Signals platform. Signals VitroVivo In vitro/in vivo biological data management module within the Signals platform. Inventory Chemical and sample inventory management built directly within Signals Notebook. Barcode scanning, location tracking, automatic low-stock alerts, material traceability. Compliance 21 CFR Part 11 (audit trails, e-signatures, version control, page locking), GxP-ready, IP protection (sign/close/witness workflows). SOC 2
Genemod LIMS & ELN Overview: Features, Pricing & Who It’s For (2026)
Who Genemod competes with Genemod is not competing with STARLIMS, BIOVIA, or Waters NuGenesis. It competes with Benchling, Labguru, and Scispot — cloud-native, modern LIMS/ELN platforms aimed at life science R&D labs transitioning away from paper notebooks and Excel. If your lab is a small-to-mid biotech, an academic research group, or an early-stage biopharma team that needs an affordable, easy-to-deploy unified LIMS and ELN, Genemod is in the right comparison set. If your lab is a regulated QC or manufacturing environment requiring a fully validated enterprise LIMS, the enterprise products in this series are more appropriate. Genemod is a Seattle-area software company that builds a unified LIMS and ELN platform for life science research labs. Founded in 2017 or 2018 (Tracxn and PitchBook report slightly different dates) by Jacob Lee (CEO) and Jin Choe (CTO), the company has raised $7.22 million across three funding rounds, with a $4.5 million Seed round closing in May 2023 led by Defy and LDV Partners (Tracxn). Other investors include Canaan, Cercano Management, Dolby Family Ventures, and Looking Glass Capital (PitchBook, 8 investors total). The company participated in SLAS 2024, one of the primary lab automation and screening conferences in the industry. Genemod’s core pitch is consolidation: replace the fragmented mix of Excel spreadsheets, Google Docs, physical freezer logs, and paper notebooks that most small and mid-size labs still operate on, and do it in a single cloud-native platform at a price point below the enterprise LIMS market. The platform manages 10 million+ records (genemod.net homepage). Its most praised feature — confirmed across every independent review source — is the visual freezer management system, which replicates the physical layout of a lab’s freezers on-screen. This article draws on genemod.net (all product, pricing, solutions, and FAQ pages), Tracxn, PitchBook, Crunchbase, G2, Capterra, Sourceforge, the Labsistant competitor pricing page (March 2026 verification, attributed as competitor-authored), and the Genemod pricing FAQ. Genemod has not reviewed, sponsored, or paid for this article. Company and funding context Understanding Genemod’s stage and scale is the most important context for a lab manager making a purchasing decision. This is a seed-stage startup, not a mature software company with decades of development behind it. Tracxn lists approximately 2 employees as of December 2024 (this appears to undercount; PitchBook lists 13 total employees, which is more consistent with an active multi-product software company). The company has raised $7.22M in total funding — meaningful for a seed stage, but modest relative to Benchling ($900M+) or even Scispot ($2.8M ARR on smaller funding). For lab managers, the practical implications of Genemod’s stage are: Vendor risk context for lab managers Genemod requires annual contract commitments (confirmed on FAQ). Before signing, ask specifically: what happens to your data if Genemod ceases operations or pivots; what data export formats are available and how complete they are; and what the transition plan would be to another system. These questions are standard due diligence for any startup LIMS vendor and are not a criticism of Genemod specifically — but they are more important here than for enterprise vendors. At a glance Field Details Founded 2017 or 2018 (Tracxn and PitchBook report different dates). Co-founders: Jacob Lee (CEO) and Jin Choe (CTO). HQ Seattle / Edmonds, Washington, USA (PitchBook: Edmonds, WA; SoftwareSuggest: Seattle). Employees ~13 (PitchBook). Tracxn lists 2, which appears to undercount. Funding $7.22M total over 3 rounds. Latest: $4.5M Seed, May 4, 2023, led by Defy and LDV Partners (Tracxn). Other investors: Canaan, Cercano Management, Dolby Family Ventures, Looking Glass Capital (PitchBook: 8 investors total). Platform Unified LIMS + ELN cloud-native SaaS. Single platform covering inventory (virtual freezers), consumables, order management, equipment scheduling, ELN, protocols, and audit trails. Scale 10M+ records managed (genemod.net homepage). Architecture Cloud-native SaaS hosted on AWS. Annual contracts required. No on-premise option confirmed. Compliance 21 CFR Part 11 compliance supported (FAQ). AWS infrastructure carries ISO 27001, SOC 1, SOC 2 — these are AWS’s own certifications for the infrastructure; Genemod’s own product-level SOC 2 certification is not separately confirmed in public sources. Audit trails and version control built in. AI features AI Agent LIMS (genemod.net/products/ai-lims): AI-powered workflow support, automated spreadsheet column matching, AI-driven recommendations. Described as “in-platform workflow support for every task.” API Open API framework confirmed (research.com, genemod.net FAQ). Languages English (Sourceforge). Pricing Starts at approximately $199/month (Sourceforge; Labsistant competitor page, March 2026 verification). 4 tiers, annual contracts required. 14-day free trial available. Academia plan for .edu emails (discounted, up to 10 users). No permanent free tier. Multi-year discounts available. Industries Biopharma R&D, industrial biotech, biorepository, clinical research, biomanufacturing, contract services, chemistry, diagnostics (genemod.net solutions pages). G2 profile Active, claimed by Genemod. Limited features plan. Verified reviews published. Top G2 praise themes: inventory management, ease of use, user interface, lab management, lab automation. Capterra Listed with non-incentivized verified reviews. Consistent praise for visual freezer management and responsive support. Notable events Participated in SLAS 2024 (Society for Laboratory Automation and Screening). (genemod.net/events/slas2024) What Genemod does — platform by module Genemod’s platform is organised around six functional areas, all available within a single cloud environment. The strength of each area is not uniform: inventory management is mature and heavily validated by user reviews; the ELN is newer and improving; the AI layer is early-stage. 1. Virtual freezer management and inventory (the core differentiator) This is Genemod’s most differentiated and most consistently praised feature. The virtual freezer replicates the physical layout of a lab’s actual freezers — rack by rack, shelf by shelf, box by box — in a visual on-screen interface. Scientists drag samples into their correct positions digitally, and the system maintains a real-world mirror of what is stored where. A Capterra reviewer who came from -80°C freezer management describes it as: “This software is useful for users who prefer better visualizations of real-life environment. Very easy to manage sample data.” Beyond freezers, the inventory module covers: reagent management with customisable item types (presets for common reagent categories, fully custom types for unusual materials); consumable management organised by category and location; advanced search with filters,
SciCord Overview: Features, Pricing & Who It’s For (2026)
SciCord is a cloud-based LIMS and ELN platform built specifically for pharmaceutical and biopharma laboratories. It is narrower in scope than most vendors in this series: it does not target environmental labs, clinical diagnostics, food & beverage testing, or academic research. Its design choices — a spreadsheet-paradigm no-code engine, integrated ELN and LIMS in one codebase, GxP compliance from the ground up — are all oriented at one buyer profile: regulated analytical, development, QC, and manufacturing labs in pharma and biopharma that are transitioning from paper-based or spreadsheet-based processes and need FDA 21 CFR Part 11 compliance without a long enterprise implementation. That focus is both SciCord’s greatest strength and its most important constraint. If your lab fits that profile, SciCord offers a rare combination: a unified ELN/LIMS platform deployable in as few as 30 days, at a price point that independent reviewers describe as far below what comparable feature sets cost elsewhere, with verified FDA audit performance documented across multiple named customers. If your lab sits outside pharma/biopharma — or if you need a public-facing API, a large support organisation, or a substantial peer review base — other vendors in this series will be a better fit. This article draws on scicord.com, SciCord’s published case studies (Pearl Therapeutics/AstraZeneca, Aurobindo, Singota Solutions, Formulated Solutions, Tenaz), the SciCord Gartner Market Guide announcement, LinkedIn, ZoomInfo, LeadIQ, RocketReach, G2, GetApp, and Sourceforge. SciCord has not reviewed, sponsored, or paid for this article. At a glance Field Details Legal name SciCord LLC Founded 2014 (ZoomInfo). Bootstrapped; no external funding confirmed (Crunchbase). CEO & Founder David Strauss (confirmed on LinkedIn company description). Co-founders: Paolo Matrascia and others (LeadIQ, RocketReach). HQ Raleigh, North Carolina, USA. Website address: 8601 Six Forks Road, Suite 400, Raleigh, NC 27615. Other sources list Cary, NC (suburb of Raleigh). Employees Approximately 9–11 as of early 2026 (RocketReach: 9; LeadIQ: ~11). Staff across North America and Europe. Ownership Privately owned and bootstrapped. No funding rounds on Crunchbase. Primary market Pharmaceutical and biopharma. Core verticals: R&D, Analytical Drug Development, QA, QC, Manufacturing, Stability. LinkedIn and scicord.com confirm this explicitly. Oil & gas and CDMO customers also documented in case studies. Platform SciCord Informatics Platform. Unified ELN + LIMS + LES + SDMS + eBR (electronic batch record) in one codebase. No separate module purchases required. Architecture Cloud SaaS hosted on Microsoft Azure. Also includes a SciCord Smart Client — a desktop application for instrument connectivity via RS232 or IP, which does not require granting external server access to the customer network. Key differentiator Spreadsheet paradigm: the entire platform is built around an Excel-like interface and engine. This is a no-code configuration approach where templates are built using spreadsheet formulas and layouts, not custom programming. Deployment Cloud-only SaaS (Azure). No on-premise option confirmed. Deployment in as few as 30 days per scicord.com and comparison page. Languages English and Italian (Sourceforge). Employees across North America and Europe confirmed by LeadIQ. Compliance FDA 21 CFR Part 11, GxP (GLP, GMP), ISO 17025, ALCOA+ data integrity principles. Azure cloud: GDPR, ISO 27001, HIPAA, FedRAMP, SOC 1 and SOC 2. Validation IQ/OQ packages and PQ drafting services provided. Validated solution integration confirmed in Pearl Therapeutics case study. Validation documentation available to accelerate customer’s own validation activities. API No API available (GetApp, confirmed April 2026). Integrations via web services (LIMS, SAP, ESM, Metrology), file transfer, and database access. Integrations Microsoft Excel, JMP Statistical Software, Microsoft Power BI, Spotfire, Microsoft Entra ID (confirmed on Sourceforge). Instrument connectivity via RS232/IP through Smart Client. SAP integration via web services. Pricing Not publicly listed. Quote-based. ROI calculator available on scicord.com. Sourceforge reviewer describes cost as significantly lower than alternatives with comparable features. Gartner Named a Representative Vendor in the 2025 Gartner Market Guide for LIMS (16 April 2025) and the 2025 Gartner Market Guide for ELN (5 May 2025). First time named in the LIMS guide (previously ELN only). G2 profile Listed on G2; profile has limited features and no published pricing (G2 page confirmed). Review count is very small. Alternatives page lists SciNote, CrelioHealth, SciSure, Labguru, and STARLIMS as top alternatives. Free trial / demo Demo available. Free trial not confirmed. The spreadsheet paradigm — what it means for lab managers The central architectural decision that defines SciCord — and the one lab managers most need to understand before evaluating it — is the spreadsheet paradigm. Rather than building a traditional LIMS with form-based screens and a separate ELN, SciCord built its entire platform around an Excel-like interface. Templates are created using spreadsheet-style layouts and formulas. Scientists work in an environment that looks and behaves like a structured spreadsheet. Configuration is done by building or modifying templates, not by writing code or by hiring a developer. For lab managers, this choice has concrete practical consequences: Lab manager note The spreadsheet paradigm is SciCord’s core strength, but it is also a design constraint. Labs that need complex workflow routing, multi-step analytical testing with highly structured result hierarchies, or deep clinical diagnostics functionality may find the spreadsheet model limiting at scale. Before committing, run SciCord through your most complex assay workflows in a demo environment to validate that the template engine covers your specific data structures. Platform capabilities SciCord’s platform integrates five functions in a single codebase, confirmed on scicord.com/scicord-analytical-lab/: ELN (Electronic Lab Notebook) The ELN layer handles experiment documentation, protocol management, and review/approval workflows. The spreadsheet-style entry supports both structured data capture and free-form documentation. Review and approval cycles are built in, with a minimum 30% increase in reviewer turnaround efficiency cited consistently across the platform and case studies. Electronic signatures are 21 CFR Part 11 compliant. Data entry is validated in real time — out-of-specification flags, SOP adherence checks, and expired reagent restrictions are built into templates. LIMS (Laboratory Information Management System) Sample management covers registration with barcode identification, receipt date, sampling date, and batch number. Chain-of-custody tracking and audit trails for all actions are maintained. Sample and reagent inventory is tracked. Instrument interfacing (RS232 or IP) is handled via the
Scispot Review: Features, Pricing & Who It’s For (2026)
Scispot is a cloud-based laboratory informatics platform founded in 2020 by Guru Singh and Satya Singh in Kitchener, Ontario, Canada. The company’s founding insight, as described by co-founder Satya Singh in a GeekWire interview (May 2024), was that “80% of biotech data never gets analyzed” due to paper-based processes, unique file formats, and lack of platform integration in labs. Guru Singh’s previous experience included scaling life science startups including Scientist.com, Science Exchange, and LabTwin. Satya Singh was a data platform executive at Expedia. Within weeks of launching in 2020, Scispot was accepted into Y Combinator’s Summer 2021 batch — confirmed on Scispot’s own blog and the Y Combinator company directory. The company has also completed programmes at Creative Destruction Lab (CDL) in Seattle. According to PitchBook, total funding raised is $606,000 from 11 investors including Communitech, Ontario Genomics, the Federal Economic Development Agency for Southern Ontario, Alliance of Angels, and Creative Destruction Lab. PitchBook lists 23 total employees as of its most recent data point. Scispot positions itself not as a traditional LIMS but as a “Lab Operating System” (LabOS) — a no-code, unified platform integrating ELN, LIMS, and SDMS capabilities in a single system, with a strong emphasis on data integration via its proprietary GLUE engine and AI-powered automation via its Scibot assistant. This article draws exclusively on Scispot’s official website and pricing page, Y Combinator’s company directory, PitchBook, Tracxn, Crunchbase, GeekWire, the Indee Labs press release, G2, Software Advice, and GetApp. Scispot has not reviewed, sponsored, or paid for this article. At a glance Field Details Vendor Scispot Inc. (operating as Scispot.io) Founded 2020 Headquarters Kitchener, Ontario, Canada Co-founders Guru Singh (CEO) and Satya Singh (CPO/COO) Accelerators Y Combinator Summer 2021 batch; Creative Destruction Lab (CDL) Seattle Investors Communitech, Ontario Genomics, FEDAS, Alliance of Angels, Creative Destruction Lab, Pack Ventures (total 11 investors per PitchBook) Funding raised $606,000 (PitchBook). Revenue reported at $2.8M ARR in October 2024 (Latka/GetLatka). Employees 23 (PitchBook). 18 reported by GetLatka. YC directory states 16. Deployment Cloud-only SaaS. Hosted on AWS (AWS GovCloud optionally for government labs). Single-tenant deployments available for high-security requirements. Platform scope LabOS: alt-ELN (Labspaces) + alt-LIMS (Labsheets) + alt-SDMS (Lakehouse) + GLUE integration engine + Scibot AI assistant + Labflows workflow automation Key industries Biotech R&D, CROs, molecular diagnostics, clinical labs, biobanking, pathology, government labs, cell and gene therapy Named customers Arrakis Therapeutics (quoted on website). Indee Labs (press release, May 2023). Persist AI (press release, July 2023). CAN Health Network (June 2025). Compliance 21 CFR Part 11, SOC 2, HIPAA, GDPR, GLP, ISO 17025, CLIA, CAP, ISO 15189 — all documented on scispot.com. Compliance confirmed in Indee Labs press release (HIPAA, SOC 2, CFR Part 11). ELN included Yes — Labspaces (alt-ELN) is part of the core platform AI assistant Scibot — NLP-powered search, workflow recommendations, AI analytics dashboards Pricing Quote-based. Tiered: Essential, Growth, Enterprise. GLUE priced separately by connectivity and data throughput. No publicly listed per-user prices. Free trial Not confirmed. Demo available. G2 rating Listed. Reviews present but count is modest. Most recent activity confirmed through 2024-2025 based on Software Advice profile. What Scispot does Scispot describes its platform as a Lab Operating System (LabOS) — a positioning that explicitly distinguishes it from traditional LIMS. Rather than adopting the established LIMS, ELN, and SDMS categories, Scispot uses the prefix “alt-” (alt-LIMS, alt-ELN, alt-SDMS) to signal a different architectural philosophy: a unified, API-first, data-science-ready platform built for biotech teams that want to eliminate the integration overhead of running separate best-of-breed tools. The platform consists of several interconnected components, all documented on scispot.com: A notable architectural choice: Scispot’s pricing page confirms the platform can be used as individual components (alt-LIMS alone, GLUE alone) or as the full LabOS bundle, providing modular entry points for labs that do not need the full suite from day one. Company context: startup scale in an enterprise market Scispot occupies an unusual position in the LIMS market. It competes for deals against platforms backed by private equity (Sapio Sciences, GHO Capital), decades of customer deployments (LabWare since 1987, LabVantage since 1981), and significant venture capital (Benchling, $418M). Scispot’s total disclosed funding is $606,000 — orders of magnitude smaller than its most prominent competitors. This context matters for buyers evaluating the platform’s long-term viability, support capacity, and enterprise readiness. PitchBook lists 23 employees; GetLatka estimated 18 in 2024; the YC directory listed 16. Revenue was reported by GetLatka at $2.8M ARR in October 2024, up from $1.7M in 2023 — indicating real and growing commercial traction, though at a scale consistent with a startup rather than an established mid-market vendor. Scale note Scispot’s team size and funding position are relevant to procurement decisions in regulated environments. Labs should evaluate: Can Scispot support a multi-site implementation? What contractual SLAs are available? What happens to data and contracts if the company’s growth trajectory changes? These are standard enterprise diligence questions that apply more acutely to a startup-scale vendor than to incumbents. Scispot’s G2 reviewers consistently praise the support team’s responsiveness — delivered partly via Slack channels — which is a model that scales differently from a traditional enterprise support organisation. Deployment and compliance Scispot is cloud-only, hosted on AWS. For government labs with higher security requirements, Scispot’s government LIMS page documents support for AWS GovCloud (US) deployment and single-tenant instances. Standard deployments are multi-tenant. Compliance documentation on scispot.com and confirmed in the Indee Labs press release (May 2023) covers: Scispot’s pricing page references a “GxP validation package for regulated deployments” as an add-on to the Growth tier. IQ/OQ/PQ validation templates and documentation are referenced on the pricing page as available within that package. Validation note Scispot’s pricing page documents IQ/OQ/PQ validation templates and “inspection prep with a dedicated team” as part of a GxP validation package. Unlike some enterprise LIMS vendors, Scispot does not appear to offer a fully pre-validated system equivalent to LabVantage Pharma’s 90-day pre-validated deployment. Labs in heavily regulated GMP environments should clarify the scope and status of validation documentation before committing. Pricing
SciSure Overview: Features, Pricing & Who It’s For (2026)
SciSure is a Scientific Management Platform (SMP) that combines ELN, LIMS, and Environmental Health & Safety (EHS) capabilities in a single system. It was formed in January 2025 through the merger of two established companies: SciShield, a Boston-based EHS software provider for research laboratories, and eLabNext, a Groningen, Netherlands-based ELN and LIMS platform that was previously owned by Eppendorf Inc. The merger was announced on 30 January 2025 via Newsfile Corp./EINPresswire and confirmed by Strattam Capital, the private equity firm backing the combined entity. SciSure’s positioning is deliberately distinct from the other LIMS vendors in this series: it is not trying to be the best standalone LIMS. Its core claim is that modern scientific organisations are harmed by running disconnected tools for research documentation, sample management, and safety compliance, and that unifying these into one system reduces administrative burden, improves compliance readiness, and creates a more coherent experience for scientists. The term “Scientific Management Platform” (SMP) was coined specifically to differentiate this broader scope from a traditional LIMS or ELN. The combined company launched with 800+ customer organisations, 550,000+ users, and 37,000+ lab groups across Europe, North America, Asia, and Australia — all figures from the merger press release. In September 2025 SciSure further expanded by acquiring Labfolder and Labregister from Labforward, adding a Berlin-based ELN and inventory system with a strong German research community presence (Newsfile Corp., 11 September 2025). G2 lists SciSure with 193 reviews at 4.2/5, drawn from the combined eLabNext and SciShield user base. As of September 2025, SciSure describes itself as trusted by over 1,000 customers worldwide. This article draws on SciSure’s official website, the merger press release (Newsfile Corp./EINPresswire, 30 January 2025), the Labfolder acquisition announcement (Newsfile Corp., 11 September 2025), the Philip Meer CEO appointment press release (republished on scisure.com, October 2024), the Strattam Capital newsroom, Crunchbase, G2, Capterra, GetApp, Sourceforge, and FitGap. SciSure has not reviewed, sponsored, or paid for this article. How SciSure was formed — understanding the component parts SciSure is a brand-new company built from two organisations with longer independent histories. Understanding those histories matters for buyers evaluating the platform’s maturity, customer base, and product integration status. Date Event Detail ~2010 eLabNext founded Founded by Erwin Seinen and Wouter de Jong as Bio-ITech B.V. in Groningen, Netherlands. Products: eLabJournal (ELN), eLabInventory (LIMS), eLabProtocols. Legal entity: Bio-ITech B.V. (confirmed on Crunchbase). Pre-2025 Eppendorf ownership eLabNext operated as a brand of Bio-ITech B.V., part of Eppendorf Group. eLabNext LinkedIn describes it as “a brand of Bio-ITech BV, part of Eppendorf Group”. QBench’s competitor blog notes eLabNext as “mainly being based in the United States.” 2023 Strattam invests Strattam Capital (Austin/San Francisco private equity) invests in SciShield. The Strattam merger press release states this enabled SciShield to “accelerate innovation” and “expand product offerings, operations, and sales teams.” Oct 2024 Philip Meer named CEO Philip Meer appointed CEO of SciShield. Press release (republished on scisure.com) describes 25+ years of global enterprise software leadership. Strattam Capital Partner Neil Willis quoted endorsing the appointment. Jan 2025 SciSure merger launch SciShield and eLabNext merge and rebrand as SciSure. Newsfile Corp./EINPresswire press release dated 30 January 2025. Combined: 800+ customer organisations, 550,000+ users, 37,000+ lab groups. Eppendorf Inc. endorsed the merger and remains a partner. Nathan Watson (SciShield founder) becomes Chief Strategy Officer. Erwin Seinen becomes CRO. Wouter de Jong becomes CPO. Sep 2025 Labfolder acquisition SciSure acquires Labfolder (ELN) and Labregister (inventory management) from Labforward. Announced Newsfile Corp., 11 September 2025. Products to operate under SciSure brand. Strengthens German research community presence. Apr 2026 Current status SciSure Inc. HQ: 3 Center Plaza, Suite 501, Boston, MA 02108. Over 1,000 customers worldwide (Labfolder acquisition press release). G2 Spring 2026 reports: badges across EHS software, ELN, LIMS, and lab inventory management categories (per SciSure website). Integration context SciSure is less than 18 months old as a merged entity as of April 2026. The merger of SciShield (EHS) and eLabNext (ELN/LIMS) represents two distinct products and teams combining under one brand. A G2 reviewer in a regulated lab environment specifically notes that the “frequency of changes and updates” adds “significant revalidation burden.” Labs evaluating SciSure should assess: (1) how deeply the EHS and ELN/LIMS modules are technically integrated vs. presented under one login; (2) the product integration roadmap; and (3) how Labfolder and Labregister will be incorporated. These are standard due diligence questions for a recently merged platform. At a glance Field Details Brand SciSure (formerly eLabNext and SciShield) Formed January 2025 (merger of SciShield and eLabNext) Pre-merger heritage eLabNext: founded ~2010, Groningen, Netherlands (ELN/LIMS). SciShield: Boston, MA (EHS software for research labs, 27,000+ labs before merger). HQ 3 Center Plaza, Suite 501, Boston, MA 02108, USA CEO Philip Meer (appointed October 2024 at SciShield, leads combined entity) Key leadership Nathan Watson (SciShield Founder, Chief Strategy Officer). Erwin Seinen (eLabNext co-founder, Chief Revenue Officer). Wouter de Jong (eLabNext co-founder, Chief Product Officer). Ownership Backed by Strattam Capital (PE, Austin/San Francisco). Strattam invested in SciShield in 2023 before the merger. Customers 800+ unique customer organisations at merger launch (January 2025). 1,000+ customers worldwide after Labfolder acquisition (September 2025). 550,000+ users at launch. 37,000+ lab groups at launch. Customer profile Fortune 100 biopharma organisations, over one-third of US R1 (top research) academic institutions, biotech, healthcare, oil & gas, food safety, retail (merger press release). Platform Scientific Management Platform (SMP): ELN + LIMS + EHS + Integrations. Also incorporates Labfolder and Labregister (acquired September 2025). Deployment Cloud (hosted in ISO-certified data centres), Private Cloud (dedicated server, custom controls), On-Premises. Confirmed on scisure.com/hosting. Note: EHS capabilities only available on Private Cloud or On-Premises. Compliance 21 CFR Part 11, GDPR, GxP, SOC 2 Type II, HIPAA, ISO 27001. Confirmed on scisure.com/solutions/startup and scisure.com/hosting. ELN included Yes — core component. Originally eLabJournal. Now branded as SciSure ELN. EHS included Yes — environmental health & safety management. Inherited from SciShield. Only fully available on Private Cloud or On-Premises hosting tiers. Pricing Not publicly listed. Quote-based. Academic, Industry, and Startup pricing tiers referenced. Free trial available
eLabFTW Overview: Features, Pricing & Who It’s For (2026)
Two things to know upfront 1. The software is completely free. eLabFTW is open-source (AGPLv3 licence). There is no per-seat charge, no paywalled feature tier, and no vendor lock-in. Every feature is available at no cost. 2. Running it requires a sysadmin. eLabFTW is server software. You cannot install it on a laptop and start using it the next day. It runs on a Linux server, deployed via Docker, and requires a systems administrator to install, configure, and maintain it. If your institution lacks this capacity, Deltablot — the company that backs the project — offers managed hosting. Both paths are covered in this article. eLabFTW is the most widely deployed open-source electronic laboratory notebook in the world. It was created by Nicolas CARPi, a research engineer at the Institut Curie in Paris, who built it to solve a problem he faced in his own lab: no suitable ELN existed that was free, flexible, and respectful of researchers’ data sovereignty. He released eLabFTW as an open-source project and developed it as a side project for years before its adoption reached a scale that led him to create Deltablot, the company that provides commercial hosting and support, in April 2019 (deltablot.com/about). As of April 2026, eLabFTW has thousands of instances running worldwide — the project stopped maintaining a list of institutions because there are too many (doc.elabftw.net/faq). In France, it is the official recommended ELN of the CNRS (Centre National de la Recherche Scientifique), the largest fundamental science agency in Europe, following a competitive selection and deployment process with Deltablot and partner company Easter Eggs. In Germany, it is described in the official documentation as “ubiquitous” at universities and private companies. Community meetings run bi-monthly with participants from institutions across Europe, Asia, and North America. No other ELN in this series — and none in the commercial market — comes close to eLabFTW’s breadth of institutional adoption in academic research. That breadth has a structural reason: when software is free, institutions that could never justify a per-seat licence budget can deploy it. Thousands of research groups at universities, institutes, startups, and public research organisations that could not afford proprietary ELNs have chosen eLabFTW specifically because the barrier to adoption is a server and a sysadmin, not a budget line. This article draws on elabftw.net, deltablot.com, doc.elabftw.net (official documentation), the GitHub repository (elabftw/elabftw), the Deltablot blog, Nicolas CARPi’s startup.info interview (September 2023), his LinkedIn activity, the eLabFTW community meeting summaries, and G2. eLabFTW and Deltablot have not reviewed, sponsored, or paid for this article. Understanding the open-source model — what it means practically eLabFTW is licensed under the AGPLv3 licence. This means: the source code is publicly available on GitHub; you can download, inspect, modify, and deploy it for free; there are no hidden features unlocked by payment; and any modifications you distribute must also be made open-source. The development roadmap and issue tracker are entirely public on GitHub — there is no private backlog, no behind-closed-doors feature development. For lab managers, this has three practical implications that are fundamentally different from every other vendor in this series: The IT dependency Open-source does not mean easy to set up. The official elabftw.net homepage states plainly: “eLabFTW should be installed on a server. This means it is not a software that you can download and install on your computer. It must be installed, configured and maintained by a Systems Administrator. If you’re not familiar with containerized services (Podman/Docker/K8s) and GNU/Linux server administration, we recommend our managed hosted solution.” For lab managers at institutions with central IT infrastructure or a technical research data manager, this barrier is modest. For lab managers at small groups without IT support, the Deltablot PRO Hosting service is the practical path to adoption. At a glance Field Details Software eLabFTW — free, open-source electronic laboratory notebook (AGPLv3 licence) Backing company Deltablot (Paris, France). Founded April 2019 by Nicolas CARPi. Creator Nicolas CARPi, research engineer (Institut Curie). Creator, lead developer, and CEO of Deltablot. Current version 5.5 (deltablot.com blog, 2026). Active development with frequent releases. Primary scope ELN (Electronic Lab Notebook). Also includes a resource/inventory database. Not a full LIMS. Deployment Self-hosted (Docker on Linux server, managed by sysadmin) or Deltablot PRO Hosting (managed SaaS). Software cost Zero. 100% free. All features included. No paywalled tiers. Hosting/support cost Free for self-hosted. Deltablot PRO Hosting: quote-based (four tiers confirmed, no published prices). PRO Support for self-hosters: quote-based. Adoption Thousands of instances worldwide (doc.elabftw.net/faq). CNRS (France) official recommended ELN. Ubiquitous in German universities (official documentation). Named institution supporters: University of Freiburg, Georg-August-University Göttingen, French National Research Institute for Sustainable Development (GitHub sponsors). Languages 21+ languages (elabftw.net). Active translations contributed by community. Key features Experiment documentation, protocol templates, resource/inventory database, file attachments, tags and search, electronic signing, trusted timestamping (RFC 3161), blockchain timestamping (Bloxberg), API, team collaboration, SAML/LDAP SSO, 2FA, audit trail, FAIR data export. Compliance GMP compliance guidance document available (doc.elabftw.net). Trusted timestamping supports regulatory recordkeeping. 21 CFR Part 11: partial — audit trail, electronic signatures, and timestamping are confirmed; full reauthentication at signing (required by §11.200(a)(1)) was an open feature request as of July 2025 (GitHub issue #5782). Regulated labs should validate their specific requirements before deployment. API Full REST API. Official Python client (elabapi-python). Community clients: Perl, LabView, Matlab, R. API workshop available on GitHub. Data sovereignty Data stays on your server (self-hosted) or in Deltablot-managed infrastructure. No telemetry, no tracking cookies (confirmed by Nicolas CARPi, startup.info interview). GDPR-compliant. SecNumCloud option (EU-certified French cloud) available for maximum sovereignty. ELN Consortium Member. Promotes the open .eln interoperability format (RO-Crate-based). G2 profile Listed with verified reviews. G2 reviews describe eLabFTW as easy to use, feature-rich, and good for experiment collaboration. Review count is limited compared to commercial ELNs. Community Bi-monthly community meetings. RDM (Research Data Manager) Club with monthly meetings. Template sharing hub in development (pre-alpha as of January 2026). Active GitHub with many contributors. What eLabFTW does — and what it does not Understanding eLabFTW’s scope is the most important
Labguru ELN LIMS Overview: Features, Pricing & Who It’s For (2026)
Labguru is a cloud-based ELN and LIMS platform built specifically for life science and pharmaceutical labs. It combines an Electronic Lab Notebook, a Laboratory Information Management System, inventory management, and informatics tools in a single system. Since April 2024 it has been owned by Battery Ventures, and as of July 2025 it operates under the newly created Cenevo brand — a merger of Labguru and Titian Software (the UK-based sample management company). The Labguru product name, website, and support infrastructure remain in active use alongside the Cenevo brand, and the article below treats them accordingly. One framing distinction matters upfront: Labguru is widely described — by independent reviewers and competitor analyses alike — as an ELN-first, LIMS-second platform. The Battery Ventures acquisition press release (Business Wire, April 2024) itself positions Labguru’s core strength as lab data management, ELN, and informatics, with LIMS as one component of that broader suite. Labs evaluating Labguru primarily for QC-heavy analytical testing workflows with complex result calculations or batch management should read the “Who it’s for” section carefully. This article draws on labguru.com, the Battery Ventures acquisition press release (Business Wire, 17 April 2024), the Cenevo rebrand press release (PRNewswire, 30 July 2025), the Alantra sell-side advisory announcement, The Connected Lab blog (Thermo Fisher, 26 June 2024), the Labguru 2024 Year in Review blog, G2 (163 reviews, 4.6/5), Capterra, Sourceforge, QBench’s independent competitor analyses (August 2025, January 2026), and CB Insights. Labguru has not reviewed, sponsored, or paid for this article. Corporate history and ownership — the Cenevo context The founding year of Labguru appears as either 2007 or 2008 across different sources: the Battery Ventures Business Wire press release and Alantra both cite 2007; the Cenevo About Us page and CB Insights both cite 2008. The discrepancy likely reflects the difference between when the founding idea was developed and when the legal entity (BioData Inc.) was formally incorporated. The article notes both. Understanding the ownership chain is important context for any multi-year software commitment: Date Event Detail 2007/2008 Founded Founded by Jonathan Gross (founder and CTO) in response to lab data management frustration. Legal entity: BioData Inc. HQ listed at 1900 West Park Drive, Westborough, Massachusetts (CB Insights); Cambridge, MA also cited (finsmes.com). Pre-2024 Holtzbrinck Digital Owned by Holtzbrinck Digital, the digital investment arm of Holtzbrinck Publishing Group (a German publishing house). Also noted as a previous investor: Digital Science (CB Insights). Holtzbrinck described Labguru’s development as positioning it as a “tier-1 lab-management software company.” Apr 2024 Battery Ventures acquires Battery Ventures (Boston-based global technology investment firm) acquires Labguru (BioData Inc.) from Holtzbrinck Digital. Terms undisclosed. Financial advisor to Holtzbrinck: Alantra. Labguru joins Battery’s existing portfolio company Titian Software. CEO Ariel Yarnitsky and founder/CTO Jonathan Gross confirmed to remain in their roles (Business Wire). Jun 2022 Titian/Battery relationship Titian Software (founded 1999, London, UK — sample management software) received a significant investment from Battery Ventures in June 2022 (Cenevo press release). This predates the Labguru acquisition. Jul 2025 Cenevo rebrand Titian Software and Labguru rebrand together as Cenevo (PRNewswire, 30 July 2025). The combined entity is headquartered in London, UK. Labguru and Mosaic (Titian’s sample management platform) continue as products under the Cenevo brand. New CEO: Keith Hale. Jonathan Gross becomes Chief Product Officer at Cenevo. Over 950 customers combined; 45,000+ scientist users; 200+ staff; offices in UK, US, Israel, and Poland. Apr 2026 Current status labguru.com is active. Product marketed under the Labguru brand within Cenevo. G2 listing: “Labguru ELN LIMS” — 163 reviews, 4.6/5. Thermo Fisher Scientific partnership active (signed June 2024). Cenevo and Labguru — what it means for buyers The Cenevo rebrand (July 2025) brings Labguru and Titian’s Mosaic sample management platform under one corporate roof. The Cenevo press release explicitly commits that “the trusted Labguru and Mosaic solutions are and will continue to be a core part of our identity, both stand-alone or combined.” Labs evaluating Labguru in 2026 are buying into a Battery Ventures-backed, Cenevo-operated platform. If combined Labguru+Mosaic sample management coverage is relevant to your organisation, the Cenevo relationship is worth exploring. If you only need ELN/LIMS, Labguru operates as a standalone product. At a glance Field Details Product Labguru ELN LIMS (cloud-based) Legal entity BioData Inc. / BioData Ltd. (Labguru trademark registered to BioData Ltd. per QBench) Founded 2007 (Business Wire, Alantra) or 2008 (Cenevo About Us, CB Insights) — both cited Founder/CTO Jonathan Gross (founder). As of July 2025: Chief Product Officer at Cenevo. CEO Ariel Yarnitsky (CEO as of Battery acquisition, April 2024). Keith Hale is CEO of the combined Cenevo entity. HQ (Labguru) Westborough, MA, USA (CB Insights). Cambridge, MA also referenced (finsmes.com). Parent company Cenevo (since July 2025). Backed by Battery Ventures. Previously owned by Holtzbrinck Digital. Cenevo HQ London, UK Users 120,000+ scientists (Battery acquisition press release, April 2024). 95,000+ on Capterra. 45,000+ across combined Cenevo (Labguru + Mosaic). Customers 950+ combined Cenevo customers (Cenevo press release). Labguru described as serving “hundreds of thousands of scientists” in Battery press release. Industries Biotech, pharma, agritech, foodtech, chemical manufacturing, academic research, and industrial labs. Confirmed across labguru.com and Battery press release. Platform scope ELN + LIMS + Inventory Management + Equipment Management + Informatics/AI tools + Protocol Management + Automation + API Primary positioning ELN-first. Multiple independent sources characterise Labguru as ELN-first with LIMS as a secondary component. Deployment Cloud-only. Confirmed across all sources. Web-based; accessible from desktops and mobile devices. No on-premise option confirmed. Languages English, French, Hebrew, Russian, Spanish (Sourceforge) Compliance FDA 21 CFR Part 11, GxP (GLP, GMP). ISO 27001 certified (SoftwareAdvice). Confirmed on labguru.com and multiple review platforms. Pricing Not publicly listed. Quote-based. Academic, Industry, and Startup tiers referenced across review platforms. Free trial available (Sourceforge, confirmed multiple sources). G2 rating 4.6/5 from 163 reviews (G2 November 2025 lab category listing). LIMS-specific sub-listing: 73 reviews as of January 2026 (QBench Best LIMS 2026 article). Top G2 positive themes: Customer Support (24), Lab Management (19), Inventory Management (19), Ease of Use (19), Organisation (16). Integrations SAP QM (deepened 2024